Q9BSJ8

PTMD Annotation Information

※ Protein Information

Tag	Content
UniProt Accession	ESYT1_HUMAN; Q9BSJ8;
Entrez ID	23344
GenBank Protein ID	NM_001184796.1; NM_015292.2;
GenBank Nucleotide ID	NP_001171725.1; NP_056107.1;
Protein Name	Extended synaptotagmin-1 (E-Syt1) (Membrane-bound C2 domain-containing protein)
Gene Name	ESYT1; FAM62A; KIAA0747; MBC2
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport (By similarity). Binds calcium (via the C2 domains) and translocates to sites of contact between the endoplasmic reticulum and the cell membrane in response to increased cytosolic calcium levels. Helps tether the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane. Functional Description Binds glycerophospholipids in a barrel-like domain and may play a role in cellular lipid transport (By similarity). Binds calcium (via the C2 domains) and translocates to sites of contact between the endoplasmic reticulum and the cell membrane in response to increased cytosolic calcium levels. Helps tether the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane.
Sequence (Fasta)	MERSPGEGPS PSPMDQPSAP SDPTDQPPAA HAKPDPGSGG QPAGPGAAGE ALAVLTSFGR 60 RLLVLIPVYL AGAVGLSVGF VLFGLALYLG WRRVRDEKER SLRAARQLLD DEEQLTAKTL 120 YMSHRELPAW VSFPDVEKAE WLNKIVAQVW PFLGQYMEKL LAETVAPAVR GSNPHLQTFT 180 FTRVELGEKP LRIIGVKVHP GQRKEQILLD LNISYVGDVQ IDVEVKKYFC KAGVKGMQLH 240 GVLRVILEPL IGDLPFVGAV SMFFIRRPTL DINWTGMTNL LDIPGLSSLS DTMIMDSIAA 300 FLVLPNRLLV PLVPDLQDVA QLRSPLPRGI IRIHLLAARG LSSKDKYVKG LIEGKSDPYA 360 LVRLGTQTFC SRVIDEELNP QWGETYEVMV HEVPGQEIEV EVFDKDPDKD DFLGRMKLDV 420 GKVLQASVLD DWFPLQGGQG QVHLRLEWLS LLSDAEKLEQ VLQWNWGVSS RPDPPSAAIL 480 VVYLDRAQDL PLKKGNKEPN PMVQLSIQDV TQESKAVYST NCPVWEEAFR FFLQDPQSQE 540 LDVQVKDDSR ALTLGALTLP LARLLTAPEL ILDQWFQLSS SGPNSRLYMK LVMRILYLDS 600 SEICFPTVPG CPGAWDVDSE NPQRGSSVDA PPRPCHTTPD SQFGTEHVLR IHVLEAQDLI 660 AKDRFLGGLV KGKSDPYVKL KLAGRSFRSH VVREDLNPRW NEVFEVIVTS VPGQELEVEV 720 FDKDLDKDDF LGRCKVRLTT VLNSGFLDEW LTLEDVPSGR LHLRLERLTP RPTAAELEEV 780 LQVNSLIQTQ KSAELAAALL SIYMERAEDL PLRKGTKHLS PYATLTVGDS SHKTKTISQT 840 SAPVWDESAS FLIRKPHTES LELQVRGEGT GVLGSLSLPL SELLVADQLC LDRWFTLSSG 900 QGQVLLRAQL GILVSQHSGV EAHSHSYSHS SSSLSEEPEL SGGPPHITSS APELRQRLTH 960 VDSPLEAPAG PLGQVKLTLW YYSEERKLVS IVHGCRSLRQ NGRDPPDPYV SLLLLPDKNR 1020 GTKRRTSQKK RTLSPEFNER FEWELPLDEA QRRKLDVSVK SNSSFMSRER ELLGKVQLDL 1080 AETDLSQGVA RWYDLMDNKD KGSS 1105 Fasta Sequence >Q9BSJ8\|ESYT1; FAM62A; KIAA0747; MBC2\|Homo sapiens (Human) MERSPGEGPSPSPMDQPSAPSDPTDQPPAAHAKPDPGSGGQPAGPGAAGEALAVLTSFGRRLLVLIPVYLAGAVGLSVGFVLFGLALYLGWRRVRDEKERSLRAARQLLDDEEQLTAKTLYMSHRELPAWVSFPDVEKAEWLNKIVAQVWPFLGQYMEKLLAETVAPAVRGSNPHLQTFTFTRVELGEKPLRIIGVKVHPGQRKEQILLDLNISYVGDVQIDVEVKKYFCKAGVKGMQLHGVLRVILEPLIGDLPFVGAVSMFFIRRPTLDINWTGMTNLLDIPGLSSLSDTMIMDSIAAFLVLPNRLLVPLVPDLQDVAQLRSPLPRGIIRIHLLAARGLSSKDKYVKGLIEGKSDPYALVRLGTQTFCSRVIDEELNPQWGETYEVMVHEVPGQEIEVEVFDKDPDKDDFLGRMKLDVGKVLQASVLDDWFPLQGGQGQVHLRLEWLSLLSDAEKLEQVLQWNWGVSSRPDPPSAAILVVYLDRAQDLPLKKGNKEPNPMVQLSIQDVTQESKAVYSTNCPVWEEAFRFFLQDPQSQELDVQVKDDSRALTLGALTLPLARLLTAPELILDQWFQLSSSGPNSRLYMKLVMRILYLDSSEICFPTVPGCPGAWDVDSENPQRGSSVDAPPRPCHTTPDSQFGTEHVLRIHVLEAQDLIAKDRFLGGLVKGKSDPYVKLKLAGRSFRSHVVREDLNPRWNEVFEVIVTSVPGQELEVEVFDKDLDKDDFLGRCKVRLTTVLNSGFLDEWLTLEDVPSGRLHLRLERLTPRPTAAELEEVLQVNSLIQTQKSAELAAALLSIYMERAEDLPLRKGTKHLSPYATLTVGDSSHKTKTISQTSAPVWDESASFLIRKPHTESLELQVRGEGTGVLGSLSLPLSELLVADQLCLDRWFTLSSGQGQVLLRAQLGILVSQHSGVEAHSHSYSHSSSSLSEEPELSGGPPHITSSAPELRQRLTHVDSPLEAPAGPLGQVKLTLWYYSEERKLVSIVHGCRSLRQNGRDPPDPYVSLLLLPDKNRGTKRRTSQKKRTLSPEFNERFEWELPLDEAQRRKLDVSVKSNSSFMSRERELLGKVQLDLAETDLSQGVARWYDLMDNKDKGSS

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Tyrosine Phosphorylation	Neuroblastoma		U	Y822	24349301
1	[Reference]: Increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)

※ Disease Cross-ref Annotation

Database	Annotation
GWASdb (count: 1)	rs2271192; Type 2 diabetes; type 2 diabetes mellitus

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 53) (view all)	10 RSPGEGPSPSPMDQP dbPAF 1009 GRDPPDPYVSLLLLP dbPAF 1011 DPPDPYVSLLLLPDK dbPAF 1022 LPDKNRGTKRRTSQK dbPAF 1032 RTSQKKRTLSPEFNE dbPAF 1034 SQKKRTLSPEFNERF dbPAF 1058 QRRKLDVSVKSNSSF dbPAF 1063 DVSVKSNSSFMSRER dbPAF 1064 VSVKSNSSFMSRERE dbPAF 1067 KSNSSFMSRERELLG dbPAF 1103 MDNKDKGSS**** dbPAF 1104 DNKDKGSS*** dbPAF 119 EEQLTAKTLYMSHRE dbPAF 12 PGEGPSPSPMDQPSA dbPAF 121 QLTAKTLYMSHRELP dbPAF 123 TAKTLYMSHRELPAW dbPAF 269 MFFIRRPTLDINWTG dbPAF 324 QDVAQLRSPLPRGII dbPAF 347 GLSSKDKYVKGLIEG dbPAF 356 KGLIEGKSDPYALVR dbPAF 359 IEGKSDPYALVRLGT dbPAF 366 YALVRLGTQTFCSRV dbPAF 4 **MERSPGEGPSP dbPAF 453 LEWLSLLSDAEKLEQ dbPAF 511 QLSIQDVTQESKAVY dbPAF 514 IQDVTQESKAVYSTN dbPAF 580 DQWFQLSSSGPNSRL dbPAF 588 SGPNSRLYMKLVMRI dbPAF 626 SENPQRGSSVDAPPR dbPAF 627 ENPQRGSSVDAPPRP dbPAF 677 VKGKSDPYVKLKLAG dbPAF 686 KLKLAGRSFRSHVVR dbPAF 77 LAGAVGLSVGFVLFG dbPAF 820 RKGTKHLSPYATLTV dbPAF 822 GTKHLSPYATLTVGD dbPAF 824 KHLSPYATLTVGDSS dbPAF 826 LSPYATLTVGDSSHK dbPAF 830 ATLTVGDSSHKTKTI dbPAF 831 TLTVGDSSHKTKTIS dbPAF 841 TKTISQTSAPVWDES dbPAF 860 IRKPHTESLELQVRG dbPAF 88 VLFGLALYLGWRRVR dbPAF 896 LCLDRWFTLSSGQGQ dbPAF 928 EAHSHSYSHSSSSLS dbPAF 933 SYSHSSSSLSEEPEL dbPAF 941 LSEEPELSGGPPHIT dbPAF 948 SGGPPHITSSAPELR dbPAF 949 GGPPHITSSAPELRQ dbPAF 950 GPPHITSSAPELRQR dbPAF 959 PELRQRLTHVDSPLE dbPAF 963 QRLTHVDSPLEAPAG dbPAF 981 QVKLTLWYYSEERKL dbPAF 982 VKLTLWYYSEERKLV dbPAF
Acetylation (count: 7) (view all)	138 VSFPDVEKAEWLNKI PLMD 189 TRVELGEKPLRIIGV PLMD 197 PLRIIGVKVHPGQRK PLMD 417 DDFLGRMKLDVGKVL PLMD 493 RAQDLPLKKGNKEPN PLMD 679 GKSDPYVKLKLAGRS PLMD 817 LPLRKGTKHLSPYAT PLMD
Ubiquitination (count: 25) (view all)	1018 SLLLLPDKNRGTKRR PLMD 1054 LDEAQRRKLDVSVKS PLMD 1060 RKLDVSVKSNSSFMS PLMD 118 DEEQLTAKTLYMSHR PLMD 138 VSFPDVEKAEWLNKI PLMD 189 TRVELGEKPLRIIGV PLMD 197 PLRIIGVKVHPGQRK PLMD 231 EVKKYFCKAGVKGMQ PLMD 33 QPPAAHAKPDPGSGG PLMD 344 AARGLSSKDKYVKGL PLMD 349 SSKDKYVKGLIEGKS PLMD 355 VKGLIEGKSDPYALV PLMD 417 DDFLGRMKLDVGKVL PLMD 422 RMKLDVGKVLQASVL PLMD 493 RAQDLPLKKGNKEPN PLMD 497 LPLKKGNKEPNPMVQ PLMD 546 QELDVQVKDDSRALT PLMD 662 EAQDLIAKDRFLGGL PLMD 671 RFLGGLVKGKSDPYV PLMD 673 LGGLVKGKSDPYVKL PLMD 681 SDPYVKLKLAGRSFR PLMD 817 LPLRKGTKHLSPYAT PLMD 835 GDSSHKTKTISQTSA PLMD 855 SASFLIRKPHTESLE PLMD 987 WYYSEERKLVSIVHG PLMD
Malonylation (count: 6)	1054 LDEAQRRKLDVSVKS PLMD 197 PLRIIGVKVHPGQRK PLMD 235 YFCKAGVKGMQLHGV PLMD 493 RAQDLPLKKGNKEPN PLMD 497 LPLKKGNKEPNPMVQ PLMD 833 TVGDSSHKTKTISQT PLMD